Navigation Links
Journal of Biological Chemistry names new editor-in-chief

BETHESDA, Md., Dec. 6, 2010 /PRNewswire-USNewswire/ – The Journal of Biological Chemistry announced today that Martha Fedor, a faculty member at The Scripps Research Institute in La Jolla, Calif., has been named the journal's next editor-in-chief.


Fedor, whose five-year term will begin Jan. 1, will succeed the journal's longtime editor, Herbert Tabor, a distinguished researcher at the National Institutes of Health who has steered the highly cited journal for the past four decades. Fedor will be the first female leader in the journal's 106-year history.

"I am delighted that Dr. Fedor has agreed to serve as editor-in-chief of the JBC," said Suzanne Pfeffer, president of American Society for Biochemistry and Molecular Biology, which publishes the JBC and two other journals. "She brings a clear vision for how to maintain JBC's excellence while incorporating emerging areas at this exciting juncture in biochemical and molecular biological research.  Having served as a JBC associate editor, she understands well the complexities of the journal's operations."

Fedor, who holds a bachelor's degree in zoology from the University of Michigan and a Ph.D. in molecular biology from the University of California, Berkeley, has served as an associate editor for the JBC since 2006, and her research focus is RNA assembly and catalysis.

"I am honored and thrilled to have this opportunity to guide the JBC into the future," Fedor said. "I am particularly grateful for Herb Tabor's confidence in my ability to take on his role in the journal that has become an icon through his outstanding leadership. I will be relying on his wisdom and on the collective wisdom and support of the JBC associate editors and the editorial board as we work together to meet the highest standards in serving the scientific community."

Tabor, who in late August asked that a search begin for his replacement, will assume the role of emeritus editor after serving as co-editor with Fedor for the first year of her term.

"Marty is poised to maintain the journal's prestige and keep it positioned on the leading edge of biochemistry," Tabor said. "She has proved repeatedly, as a researcher and as a JBC associate editor, that she has what it takes to shepherd the journal into a new era. I have a lot of respect for her, and I feel very enthusiastic about putting the JBC's future in her capable hands."

Fedor did postdoctoral training at the University of Colorado at Boulder and Stanford University School of Medicine.  After a stint on the faculty at the University of Massachusetts Memorial Medical Center, she moved to Scripps in 1997, where she is a member of the department of chemical physiology, the department of molecular biology and the Skaggs Institute for Chemical Biology.  She is also a member of the editorial board for the journal RNA.

About the Journal of Biological Chemistry

The Journal of Biological Chemistry is the most-cited biomedical research journal in the world. It publishes papers based on original research that are judged to make a novel and important contribution to understanding the molecular and cellular basis of biological processes. The journal is published by the American Society for Biochemistry and Molecular Biology, a nonprofit scientific and educational organization with more than 12,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in various government laboratories, at nonprofit research institutions and in industry. The Society's student members attend undergraduate or graduate institutions.  For more information about ASBMB, visit  

SOURCE American Society for Biochemistry and Molecular Biology
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
2. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
3. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
6. Tips from the journals of the American Society for Microbiology
7. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
8. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
9. Publication on Tregitopes in Blood Journal of October 2008
10. The Lancets New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily
11. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):